Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?
PDF
Cite
Share
Request
Oncologic Imaging - Review
P: 75-89
January 2016

Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?

Diagn Interv Radiol 2016;22(1):75-89
1. Department of Radiology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
2. Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
3. Department of Radiology, Hospital Clínic Barcelona, Barcelona, Spain
4. Department of Radiology, Clínica Girona and Hospital Santa Caterina, Girona, Spain
5. Clinica Las Nieves, Sercosa, Jaén, Spain; Department of Radiology, Case Western Reserve University, Cleveland, Ohio, USA
6. Mestrelab Research, Santiago de Compostela, Spain
No information available.
No information available
Received Date: 14.01.2015
Accepted Date: 16.06.2015
PDF
Cite
Share
Request

ABSTRACT

Abnormal metabolism is a key tumor hallmark. Proton magnetic resonance spectroscopy (1H-MRS) allows measurement of metabolite concentration that can be utilized to characterize tumor metabolic changes. 1H-MRS measurements of specific metabolites have been implemented in the clinic. This article performs a systematic review of image acquisition and interpretation of 1H-MRS for cancer evaluation, evaluates its strengths and limitations, and correlates metabolite peaks at 1H-MRS with diagnostic and prognostic parameters of cancer in different tumor types.